跳至主要内容
临床试验/NCT02211313
NCT02211313终止不适用

Evaluation of Ureteral Stents in the Management of Stone Disease

Washington University School of Medicine2 个研究点 分布在 1 个国家目标入组 41 人开始时间: 2014年8月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
终止
入组人数
41
试验地点
2
主要终点
Change From Baseline in Pain on the 10-point Analog Pain Scale at Day 7 Post Stent Removal.

研究概览

简要总结

A thin tube, called a ureteral stent, is inserted into the ureter and is commonly used as treatment of urinary stone disease. Stents are designed to help provide drainage of the kidney in the setting of an obstructing stone, or postoperative swelling of the ureter. Though their presence is only temporary, stents are associated with a significant amount of patient discomfort and bother, which can negatively impact overall satisfaction. Over the past decades, there have been refinements in stent technology and usage philosophy. Smaller and softer stents are now available for use in patients, though studies evaluating the relative benefits have been conflicting. The investigators aim to evaluate the effect of stent size and composition upon outcomes after the treatment of stone disease, including patient comfort and satisfaction.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Over 18 years of age and willing and able to provide informed consent
  • Patients with current urinary stone disease, undergoing any of the following procedures:
  • cystoscopy with stent placement
  • ureteroscopy with intracorporeal lithotripsy

排除标准

  • Patients with compromised urinary tract due to cancer (e.g. bladder tumor, ureteral obstruction from non-GU malignancy)
  • Patients requiring bilateral surgical stone management procedure
  • Patients with any single stone exceeding 1.5 cm
  • Patients with severe concurrent disease, infection, or co-morbidity that, in the judgment of the investigator, would render the patient inappropriate for enrollment
  • Any patient who is on anticholinergic medication at baseline

研究组 & 干预措施

Ureteral stent - hydrophobic, 6 French

Active Comparator

Subjects randomized to hydrophobic stent, size 6 French

干预措施: Randomization to size 6 French soft vs. size 6 French hydrophobic ureteral stent. (Device)

Ureteral stent - soft, 6 French

Active Comparator

Subjects randomized to soft stent, size 6 French

干预措施: Randomization to size 6 French soft vs. size 6 French hydrophobic ureteral stent. (Device)

结局指标

主要结局

Change From Baseline in Pain on the 10-point Analog Pain Scale at Day 7 Post Stent Removal.

时间窗: Baseline, day 7 post stent removal

The 10-point scale ranges from 0 (zero) for no pain (minimum) to 10 for the worst possible pain (maximum). The unit of measure is 1 point on the 10-point scale.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验